We are live on ! Find out more
RGC

Redwood Grove Capital Portfolio holdings

AUM $395M
1-Year Est. Return 53.96%
This Fund
S&P 500
This Quarter Est. Return
+24.81%
1 Year Est. Return
+53.96%
3 Year Est. Return
+79.82%
5 Year Est. Return
+84.02%
10 Year Est. Return
–
AUM
$395M
AUM Growth
+$84.9M
Cap. Flow
+$13.3M
Cap. Flow %
3.37%
Top 10 Hldgs %
60.46%
Holding
27
New
5
Increased
6
Reduced
8
Closed
2

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$18.6M
2
XYL icon
Xylem
XYL
+$11.5M
3
PRIM icon
Primoris Services
PRIM
+$8.19M
4
GFL icon
GFL Environmental
GFL
+$8.09M
5
ELAN icon
Elanco Animal Health
ELAN
+$5.4M

Top Sells

Rank Stock Value
1
HUM icon
Humana
HUM
+$15.9M
2
SHLS icon
Shoals Technologies Group
SHLS
+$11.6M
3
UCTT
Ultra Clean Holdings
UCTT
+$5.36M
4
SNY icon
Sanofi
SNY
+$3.93M
5
MRK icon
Merck
MRK
+$3.62M

Sector Composition

Rank Sector Weight
1 Industrials 29.04%
2 Healthcare 24.96%
3 Technology 24.29%
4 Communication Services 6.45%
5 Consumer Discretionary 5.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
26
Merck
MRK
$375B
– –
-30,068
Closed -$3.62M
SNY icon
27
Sanofi
SNY
$110B
– –
-81,557
Closed -$3.93M
1
2

Similar funds

PCM
Pennsylvania Capital Management Huntingdon Valley, Pennsylvania $395M AUM 23.17% 1-Year Est. Return
KC
Knuff & Co Foster City, California $395M AUM 24.52% 1-Year Est. Return
SC
Steph & Co Marinette, Wisconsin $395M AUM 20.8% 1-Year Est. Return
HP
Holowesko Partners Nassau, Bahamas $395M AUM 15.17% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
ACM
Aurdan Capital Management Wayne, Pennsylvania $394M AUM 19.7% 1-Year Est. Return
XSC
X-Square Capital Guaynabo, Puerto Rico $394M AUM 44.75% 1-Year Est. Return
SSW
Stone Summit Wealth Miami, Florida $394M AUM 22.1% 1-Year Est. Return

Redwood Grove Capital's Q2 2026 Portfolio in Review

As of Q2 2026, Redwood Grove Capital held 27 positions worth $395M, up 27% from $310M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Redwood Grove Capital deployed $13.3M of net new capital in Q2 2026, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was Thermo Fisher Scientific: 38,800 shares worth $19.5M.

By sector, the portfolio is most concentrated in Industrials at 29% of assets, up from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Humana, an estimated $15.9M trimmed.

  • Redwood Grove Capital's largest Q2 2026 buy was Thermo Fisher Scientific: 38,800 shares worth $19.5M.
  • Redwood Grove Capital added most to Xylem in Q2 2026, an estimated $11.5M increase.
  • Redwood Grove Capital's biggest Q2 2026 reduction was Humana, cutting an estimated $15.9M.
  • Redwood Grove Capital fully exited Sanofi in Q2 2026, selling an estimated $3.93M.
  • Redwood Grove Capital's ten largest holdings make up 60% of its $395M portfolio in Q2 2026.
  • Redwood Grove Capital opened 5 new positions and closed 2 in Q2 2026.
  • Redwood Grove Capital's portfolio value rose 27% quarter-over-quarter to $395M.

Based on Redwood Grove Capital's 13F filing for Q2 2026, filed 14 Aug 2026.